Press release
Castrate-resistant Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Janssen R&D, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics
The latest healthcare forecast report provides an in-depth analysis of Castrate-resistant Prostate Cancer, offering comprehensive insights into the Castrate-resistant Prostate Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Castrate-resistant Prostate Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Castrate-resistant Prostate Cancer therapies. Additionally, we cover the landscape of Castrate-resistant Prostate Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Castrate-resistant Prostate Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Castrate-resistant Prostate Cancer space.
To Know in detail about the Castrate-resistant Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Castrate-resistant Prostate Cancer Market Forecast [https://www.delveinsight.com/sample-request/castrate-resistant-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Castrate-resistant Prostate Cancer Market Report:
*
The Castrate-resistant Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx and atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.
*
In August 2024, Nuvation Bio announced that the U.S. Food and Drug Administration has approved its investigational new drug application to assess NUV-1511, the first clinical candidate from the company's innovative drug-drug conjugate (DDC) platform.
*
In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
*
Key Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis, Hinova, AstraZeneca, Effector Therapeutics, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, and others.
*
Key Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), LAE001, 177Lu-PSMA617, HC-1119, AZD4635, tomivosertib (eFT508), Enzalutamide, and others
*
The Castrate-resistant Prostate Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Castrate-resistant Prostate Cancer pipeline products will significantly revolutionize the Castrate-resistant Prostate Cancer market dynamics.
*
Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives
*
The total diagnosed cases of CRPC in the 7MM were found to be 2,692,615 in 2021 which is expected to grow during the study period
*
The total prevalent cases of prostate cancer in the 7MM were observed to be 7,726,394 cases in 2021 which is expected to grow during the study period (2019-2032). In total prevalent cases of the 7MM; the US accounted for highest number of cases which were 3,581,872 cases in 2021
*
Among the EU-5 countries, Germany had the highest diagnosed prevalence of Prostate Cancer, followed by France and Italy. On the other hand, Spain had the lowest diagnosed prevalent population in2021. Furthermore, in total diagnosed cases of the7MM; Japan accounted for 252,141cases of in 2021
Castrate-resistant Prostate Cancer Overview
Castrate-resistant prostate cancer (CRPC) is a type of prostate cancer that continues to grow and progress despite low levels of testosterone, typically achieved through androgen deprivation therapy (ADT). Initially, prostate cancer is often responsive to treatments that reduce testosterone, but over time, some cancer cells adapt and become resistant to these therapies. CRPC can manifest with rising prostate-specific antigen (PSA) levels, new symptoms, or metastasis. It is associated with a more aggressive disease course and requires alternative treatment strategies, such as chemotherapy, novel hormonal therapies, or targeted therapies, to manage the condition.
Get a Free sample for the Castrate-resistant Prostate Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/castrate-resistant-prostate-cancer-market [https://www.delveinsight.com/report-store/castrate-resistant-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Castrate-resistant Prostate Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Castrate-resistant Prostate Cancer Epidemiology Segmentation:
The Castrate-resistant Prostate Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Castrate-resistant Prostate Cancer
*
Prevalent Cases of Castrate-resistant Prostate Cancer by severity
*
Gender-specific Prevalence of Castrate-resistant Prostate Cancer
*
Diagnosed Cases of Episodic and Chronic Castrate-resistant Prostate Cancer
Download the report to understand which factors are driving Castrate-resistant Prostate Cancer epidemiology trends @ Castrate-resistant Prostate Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/castrate-resistant-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Castrate-resistant Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Castrate-resistant Prostate Cancer market or expected to get launched during the study period. The analysis covers Castrate-resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Castrate-resistant Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Castrate-resistant Prostate Cancer Therapies and Key Companies
*
Niraparib: Janssen Research & Development
*
Talzenna: Pfizer/Astellas Pharma
*
Opdivo (nivolumab): Bristol-Myers Squibb
*
LAE001: Laekna Therapeutics
*
177Lu-PSMA617: Novartis
*
HC-1119: Hinova
Discover more about therapies set to grab major Castrate-resistant Prostate Cancer market share @ Castrate-resistant Prostate Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/castrate-resistant-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Castrate-resistant Prostate Cancer Market Drivers
*
Rising Geriatric Population and High Prevalence Rate of Castrate-resistant Prostate Cancer
*
Increase in Demand for Castrate-resistant Prostate Cancer Treatment
*
Products Surge in Awareness Regarding the Treatment of Castrate-resistant Prostate Cancer
*
Innovation in drugs and developments in genomics and proteomics
Castrate-resistant Prostate Cancer Market Barriers
*
Cost Constraints
*
The Complex issue of Companion Diagnostics
*
Entry Barrier
*
Diagnostic challenges
Scope of the Castrate-resistant Prostate Cancer Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis, Hinova, AstraZeneca, Effector Therapeutics, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, and others
*
Key Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), LAE001, 177Lu-PSMA617, HC-1119, AZD4635, tomivosertib (eFT508), Enzalutamide, and others
*
Castrate-resistant Prostate Cancer Therapeutic Assessment: Castrate-resistant Prostate Cancer current marketed and Castrate-resistant Prostate Cancer emerging therapies
*
Castrate-resistant Prostate Cancer Market Dynamics: Castrate-resistant Prostate Cancer market drivers and Castrate-resistant Prostate Cancer market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Castrate-resistant Prostate Cancer Unmet Needs, KOL's views, Analyst's views, Castrate-resistant Prostate Cancer Market Access and Reimbursement
To know more about Castrate-resistant Prostate Cancer companies working in the treatment market, visit @ Castrate-resistant Prostate Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/castrate-resistant-prostate-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Castrate-resistant Prostate Cancer Market Report Introduction
2. Executive Summary for Castrate-resistant Prostate Cancer
3. SWOT analysis of Castrate-resistant Prostate Cancer
4. Castrate-resistant Prostate Cancer Patient Share (%) Overview at a Glance
5. Castrate-resistant Prostate Cancer Market Overview at a Glance
6. Castrate-resistant Prostate Cancer Disease Background and Overview
7. Castrate-resistant Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Castrate-resistant Prostate Cancer
9. Castrate-resistant Prostate Cancer Current Treatment and Medical Practices
10. Castrate-resistant Prostate Cancer Unmet Needs
11. Castrate-resistant Prostate Cancer Emerging Therapies
12. Castrate-resistant Prostate Cancer Market Outlook
13. Country-Wise Castrate-resistant Prostate Cancer Market Analysis (2019-2032)
14. Castrate-resistant Prostate Cancer Market Access and Reimbursement of Therapies
15. Castrate-resistant Prostate Cancer Market Drivers
16. Castrate-resistant Prostate Cancer Market Barriers
17. Castrate-resistant Prostate Cancer Appendix
18. Castrate-resistant Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=castrateresistant-prostate-cancer-market-to-show-remarkable-growth-trends-from-2023-to-2032-delveinsight-reports-janssen-rd-pfizer-astellas-pharma-bristolmyers-squibb-laekna-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castrate-resistant Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Janssen R&D, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics here
News-ID: 3902209 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
